×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
OCUL – ocular therapeutix, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
OCUL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/6
04:01 pm
ocul
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2/5
06:08 pm
ocul
Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates [Yahoo! Finance]
Low
Report
Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates [Yahoo! Finance]
2/5
01:28 pm
ocul
Ocular Therapeutix's Recent Stock Weakness Presents Buying Opportunity, RBC Says [Yahoo! Finance]
Medium
Report
Ocular Therapeutix's Recent Stock Weakness Presents Buying Opportunity, RBC Says [Yahoo! Finance]
2/5
10:58 am
ocul
Ocular Therapeutix (NASDAQ:OCUL) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Medium
Report
Ocular Therapeutix (NASDAQ:OCUL) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
2/5
07:18 am
ocul
Ocular Therapeutix: Q4 Earnings Snapshot [Yahoo! Finance]
Low
Report
Ocular Therapeutix: Q4 Earnings Snapshot [Yahoo! Finance]
2/5
07:17 am
ocul
Ocular Therapeutix GAAP EPS of -$0.29, revenue of $13.25M [Seeking Alpha]
Low
Report
Ocular Therapeutix GAAP EPS of -$0.29, revenue of $13.25M [Seeking Alpha]
2/5
07:00 am
ocul
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Medium
Report
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
2/4
07:46 am
ocul
Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive [Seeking Alpha]
Low
Report
Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive [Seeking Alpha]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/5
08:16 am
ocul
Form S-8 OCULAR THERAPEUTIX, INC
Low
Report
Form S-8 OCULAR THERAPEUTIX, INC
2/5
07:58 am
ocul
Form 10-K OCULAR THERAPEUTIX, INC For: Dec 31
Low
Report
Form 10-K OCULAR THERAPEUTIX, INC For: Dec 31
2/5
07:14 am
ocul
Form 8-K OCULAR THERAPEUTIX, INC For: Feb 05
Low
Report
Form 8-K OCULAR THERAPEUTIX, INC For: Feb 05
2/4
08:24 pm
ocul
Form 4 OCULAR THERAPEUTIX, INC For: Feb 02 Filed by: Notman Donald
Low
Report
Form 4 OCULAR THERAPEUTIX, INC For: Feb 02 Filed by: Notman Donald
2/4
04:11 pm
ocul
Form 144 OCULAR THERAPEUTIX, INC Filed by: Meyers Steve Lawrence
Medium
Report
Form 144 OCULAR THERAPEUTIX, INC Filed by: Meyers Steve Lawrence
2/4
04:09 pm
ocul
Form 144 OCULAR THERAPEUTIX, INC Filed by: Notman Donald
Medium
Report
Form 144 OCULAR THERAPEUTIX, INC Filed by: Notman Donald
2/2
04:30 pm
ocul
Form 144 OCULAR THERAPEUTIX, INC Filed by: Notman Donald
Medium
Report
Form 144 OCULAR THERAPEUTIX, INC Filed by: Notman Donald
2/2
04:29 pm
ocul
Form 144 OCULAR THERAPEUTIX, INC Filed by: Meyers Steve Lawrence
Medium
Report
Form 144 OCULAR THERAPEUTIX, INC Filed by: Meyers Steve Lawrence
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
Ocular Therapeutix Inc (NASDAQ: OCUL) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating and a $8.00 price target on the stock.
21.1%
6/10 Form 4 OCULAR THERAPEUTIX, INC For: Jun 06 Filed by: Mattessich Antony C. 20.0%
3/3 Form 8-K OCULAR THERAPEUTIX, INC For: Mar 03 19.7%
6/6 Form 8-K OCULAR THERAPEUTIX, INC For: Jun 06 19.4%
5/30 Form 8-K OCULAR THERAPEUTIX, INC For: May 24 17.9%
3/20 Form 4 OCULAR THERAPEUTIX, INC For: Mar 18 Filed by: SUMMER ROAD LLC 15.6%
7/26 Ocular Therapeutix™ Announces Early Assignment of Permanent and Specific J-Code (J1096) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg by the Centers for Medicare and Medicaid Services 11.0%
3/12 Form 10-K OCULAR THERAPEUTIX, INC For: Dec 31 10.5%
1/2 Form 4 OCULAR THERAPEUTIX, INC For: Dec 30 Filed by: Opaleye Management Inc. 10.1%
4/13 Form 8-K OCULAR THERAPEUTIX, INC For: Apr 13 9.0%
6/10 Form 4 OCULAR THERAPEUTIX, INC For: Jun 06 Filed by: Mattessich Antony C. 20.0%
3/3 Form 8-K OCULAR THERAPEUTIX, INC For: Mar 03 19.7%
6/6 Form 8-K OCULAR THERAPEUTIX, INC For: Jun 06 19.4%
5/30 Form 8-K OCULAR THERAPEUTIX, INC For: May 24 17.9%
3/20 Form 4 OCULAR THERAPEUTIX, INC For: Mar 18 Filed by: SUMMER ROAD LLC 15.6%
7/26 Ocular Therapeutix™ Announces Early Assignment of Permanent and Specific J-Code (J1096) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4mg by the Centers for Medicare and Medicaid Services 11.0%
3/12 Form 10-K OCULAR THERAPEUTIX, INC For: Dec 31 10.5%
1/2 Form 4 OCULAR THERAPEUTIX, INC For: Dec 30 Filed by: Opaleye Management Inc. 10.1%
4/13 Form 8-K OCULAR THERAPEUTIX, INC For: Apr 13 9.0%
TOP News Decliners
5/20
Ocular Therapeutix™ Announces Topline Results of Phase 3 Clinical Trial of OTX-TP for the Treatment of Glaucoma
-22.6%
2/25 Ocular Therapeutix™ to Present at the Cowen and Company 40th Annual Health Care Conference -16.3%
11/8 Form 8-K OCULAR THERAPEUTIX, INC For: Nov 06 -16.3%
11/12 Form 10-Q OCULAR THERAPEUTIX, INC For: Sep 30 -14.9%
11/14 Ocular Therapeutix™ to Present at the Jefferies 2019 London Healthcare Conference -12.2%
3/7 Ocular Therapeutix Inc (NASDAQ: OCUL) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -11.6%
9/26 Ocular Therapeutix™ to Present at the 2019 Cantor Global Healthcare Conference -10.3%
1/10 Form SC 13G/A OCULAR THERAPEUTIX, INC Filed by: Opaleye Management Inc. -8.5%
11/15 Ocular Therapeutix Inc (NASDAQ: OCUL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock. -8.2%
8/7 Q2/2019 6/30/2019 EPS -0.570 ZacksConsensus -0.420 ActVsEst (0.150) - Miss -8.1%
2/25 Ocular Therapeutix™ to Present at the Cowen and Company 40th Annual Health Care Conference -16.3%
11/8 Form 8-K OCULAR THERAPEUTIX, INC For: Nov 06 -16.3%
11/12 Form 10-Q OCULAR THERAPEUTIX, INC For: Sep 30 -14.9%
11/14 Ocular Therapeutix™ to Present at the Jefferies 2019 London Healthcare Conference -12.2%
3/7 Ocular Therapeutix Inc (NASDAQ: OCUL) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -11.6%
9/26 Ocular Therapeutix™ to Present at the 2019 Cantor Global Healthcare Conference -10.3%
1/10 Form SC 13G/A OCULAR THERAPEUTIX, INC Filed by: Opaleye Management Inc. -8.5%
11/15 Ocular Therapeutix Inc (NASDAQ: OCUL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock. -8.2%
8/7 Q2/2019 6/30/2019 EPS -0.570 ZacksConsensus -0.420 ActVsEst (0.150) - Miss -8.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: